Argus Upgrades Palantir to Buy After Sell-Off: Is $190 Floor?
Palantir surged into focus after blowout Q1 results and a fresh Buy rating from Argus with a $190 target, raising que...
Which Is More Tax Efficient Index Fund Or Target Date Fund
Assess tax efficiency between index funds and target-date funds, including distributions and potential tax-optimized strategies for investors.
28,288 articles
Astera Labs Chairman Manuel: Should You Sell ALAB?
A high-profile insider move has many ALAB investors wondering what comes next. This article breaks down the $60.5 mil...
This Summer’s Hottest IPOs Redefine Wealth for Families
This summer’s hottest IPOS are creating a surge of new wealth among employees and pressuring family offices to adapt ...
Shark Tank’s Kevin O’Leary Sees AI Boom, Bets on Two Paths
shark tank’s kevin o’leary identifies two booming opportunities in AI for 2026: helping small businesses deploy AI to...
Memory Stocks Jump Tuesday: Micron Rally Lifts Sector
Micron Technology led a Tuesday rally in the memory sector, with peers posting solid gains as a new AMAT collaboratio...
Here Tuesday’s Best Wall Street Calls Signal Mixed Rally
U.S. stocks and futures react to a fresh batch of analyst calls on Dynatrace, Emerson Electric, Exxon Mobil and more....
Gary Coleman’s Ex-Wife Faces Renewed Scrutiny Post Lie Test
Public scrutiny can spill over into family finances. This article examines Gary Coleman’s ex-wife faces renewed quest...
Solana Buy, Sell, Hold in 2026: A Practical Investor Guide
Solana faces both headwinds and catalysts as 2026 unfolds. This guide breaks down when to consider solana buy, sell, ...
Will Trump Bull Market Continue or End Abruptly in 2026
Geopolitical waves, like an Iran-related spillover, test whether the will trump bull market can keep delivering gains...
Have Until 2031: What Happens to Loans and Housing
A quiet demographic trend could reshape the loan landscape by 2031. This article explains what to expect for mortgage...
Pfizer Could Year-End Target Hit on 2-to-1 Trial Payoff
Pfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Should Investors Be Nervous Live Oak After CEO Sells 20K Shares
A Live Oak Bancshares CEO sold 20,000 shares for roughly $769,000 in mid-June. Is this a warning sign or routine dive...
Popular Topics
Fable
Smart Money Moves For Everyday Life
Investment Strategies In Energy Sector
Best Index Funds For Retirement
Investment Strategies
Untitled D6eff7ea
Crypto For Beginners
Best Dividend Etfs
Index
Innovative Skincare Clinical
Dutch Salary
Blue Owl
Budget
Ai Healthcare News
Penalty Vs No Penalty Depending On Lock Status